Muscle Ring Finger 1 (MuRF1) and MuRF2 are Necessary but Functionally Redundant During Developmental Cardiac Growth and Regulate E2F1-Mediated Gene Expression In Vivo by Willis, Monte S. et al.
Muscle Ring Finger 1 (MuRF1) and MuRF2 are Necessary but
Functionally Redundant During Developmental Cardiac Growth
and Regulate E2F1-Mediated Gene Expression In Vivo
Monte S. Willis1,2, Kristine M. Wadosky2, Jessica E. Rodríguez2, Jonathan C. Schisler1,
Pamela Lockyer1, Eleanor G. Hilliard1, David J. Glass3, and Cam Patterson1,4
1McAllister Heart Institute, University of North Carolina, Chapel Hill, NC
2Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC
3Novartis Institutes for Biomedical Research Inc., Cambridge, MA
4Departments of Medicine and Pharmacology, University of North Carolina, Chapel Hill, NC
Abstract
Aims—Muscle ring finger (MuRF) proteins have been implicated in the transmission of
mechanical forces to nuclear cell signaling pathways through their association with the sarcomere.
We recently reported that MuRF1, but not MurF2, regulates pathologic cardiac hypertrophy in
vivo. This was surprising given that MuRF1 and MuRF2 interact with each other and many of the
same sarcomeric proteins experimentally.
Methods and Results—Mice missing all four MuRF1 and MuRF2 alleles [MuRF1/MuRF2
double null (DN)] were born with a massive spontaneous hypertrophic cardiomyopathy and heart
failure; mice that were null for one of the genes, but heterozygous for the other (i.e. MuRF1−/−//
MuRF2+/− or MuRF1+/−//MuRF2−/−) were phenotypically identical to wild type mice.
Microarray analysis of genes differentially expressed between MuRF1/MuRF2 DN, mice missing
3 of the four alleles, and wild type mice revealed a significant enrichment of genes regulated by
the E2F transcription factor family. Over 85% of the differentially expressed genes had E2F
promoter regions (E2f:DP; p<0.001). Western analysis of E2F revealed no differences between
MuRF1/MuRF2 DN hearts and wild type hearts; however, chromatin IP studies revealed that
MuRF1/MuRF2 DN hearts had significantly less binding of E2F1 in the promoter regions of genes
previously defined to be regulated by E2F1 (p21, Brip1, and PDK4, p<0.01).
Conclusion(s)—These studies suggest that MuRF1 and MuRF2 play a redundant role in
regulating developmental physiologic hypertrophy, by regulating E2F transcription factors
essential for normal cardiac development by supporting E2F localization to the nucleus, but not
through a process that degrades the transcription factor.
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The muscle ring finger (MuRF) proteins are muscle-specific proteins implicated in the
regulation of cardiac development and contractility 1–3. Both MuRF1 and MuRF2 are found
at the M-line of the sarcomere 3–5 and affect activity of the transcription factor serum
response factor 6, 7. This has been hypothesized to occur in response to biomechanical
stimuli, suggesting that MuRF proteins have the ability to recognize stress and respond
appropriately 6. We recently found that MuRF1, but not MuRF2, regulates the development
of pathologic cardiac hypertrophy in adult mice 7. The involvement of only MuRF1 in this
process was surprising given that MuRF1 and MuRF2 are known to homo- and hetero-
dimerize 8, and have been found to redundantly target myofibrillar proteins in yeast two
hybrid studies 9. We hypothesized that MuRF1 and MuRF2 may have redundant function
during cardiac development, and therefore created mice lacking either 3 (MuRF1−/−//
MuRF2+/− or MuRF1+/−//MuRF2−/−) or 4 (MuRF1−/−//MuRF2−/−; MuRF1/MuRF2 DN)
of the MuRF1 and MuRF2 alleles and compared them functionally. We then analyzed these
hearts for redundancies by gene expression profiling.
Materials and Methods
Generation of MuRF1−/− // MuRF2 −/− mice
All mouse experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) review board at the University of North Carolina and were in compliance with the
rules governing animal use as published by the National Institutes of Health. We generated
MuRF1−/− // MuRF2 −/−(MuRF1/MuRF2 double null (DN)) mice using mice previously
characterized by our laboratory (129S/C57BL6 background) 7. Briefly, we mated MuRF1 −/
− and MuRF2 −/−mice to generate double heterozygous mice (MuRF1+/− //MuRF2+/−).
Double heterozygous mice were then mated to generate double null and wild type controls
on the same background. Equal numbers of both sexes were included in the studies and
equal numbers of male and female offspring were identified. The significant decrease in
expected MuRF1/MuRF2 DN mice (only 4 out of 268 pups born/Chi2=0.0000255) resulted
in a limited number of MuRF1/MuRF2 DN breeding pairs. For this reason, we chose to
breed the double null mice to either MuRF1+/−//MuRF2−/− or MuRF1−/−//MuRF2+/−
mice, resulting in the production of mice lacking 3 of the 4 MuRF1 and MuRF2 alleles (i.e.
MuRF1−/−MuRF2+/− or MuRF1+/−MuRF2−/−) in addition to MuRF1/MuRF2 DN and
wild type mice. At the time of harvest, mice were exposed to isoflurane in an enclosed
environment until respiration stopped; cervical dislocation was then performed and then
tissues were immediately removed for analysis.
Experimental design
Histological analysis was performed on MuRF1/MuRF2 DN mice either within 12 hours
post-mortem (for those mice that died post-natally) or at 12 weeks of age (for surviving
mice). Both experimental groups (i.e. those that died post-natally and those that lived)
contained an even distribution of male and female mice. Hearts were dissected from the
body and perfused with 4% paraformaldehyde. Paraffin sections were stained with H&E,
Masson’s Trichrome, or Lectin as previously described7.
Echocardiography was performed on conscious mice by both M-mode and two-dimensional
imaging using the Vevo 770 ultrasound system as previously described 7 at 12 weeks of age.
Real time PCR analysis of gene expression
For gene expression studies, a two-step reaction was used to determine mRNA expression of
fetal genes associated with cardiac hypertrophy as previously described 7.
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RNA extraction and microarray processing
Total RNA was isolated from 12-week-old mouse cardiac apices using the All Prep DNA/
RNA/Protein isolation kit (Qiagen, Inc., Valencia CA) was verified for integrity using the
BioAnalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA). RNA samples labeled
with cyanine-5 CTP in a T-7 transcription reaction using the Agilent Low Input Linear RNA
Amplification/Labeling System were hybridized to 4×44K microarray slides (Agilent
GPL4134) in the presence of equimolar concentrations of cyanine-3 CTP-labeled mouse
reference RNA 10. Slides were hybridized, washed, and scanned on an Axon 4000b
microarray scanner and data were processed using Feature Extraction (version 9.1.3.1,
Agilent). Post-processing included Loess- 11, 12 and median-centered normalization using
Genespring GX (version 10.0.1 Build 81217; Agilent). The Database for Annotation,
Visualization and Integrated Discovery (DAVID) 13, 14 identified significantly enriched
functional clusters (high classification stringency, group enrichment score of >1.3, p<0.05)
using multiple annotation libraries from lists of differentially expressed genes, using the
genes represented on the microarray as background (see Supplemental Table 1 for DAVID
annotation libraries used). Complete, MIAME-compliant datasets were deposited with the
Gene Expression Omnibus of the National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/geo/) 15, and are accessible through GEO Series accession number
GSE14512.
Chromatin IP (ChIP) analysis of E2F1
Chromatin IP (ChIP) from heart tissues was based on the Farnham protocol (http://
farnham.genomecenter.ucdavis.edu/). p21, Brip1, and PDK4 promoter regions were
investigated because these were genes differentially expressed in the microarray analyses for
which E2F1 regulation had been published in the peer-reviewed literature and primers had
been described in the mouse. PCR primers were designed to amplify a 96, 148, and 128 bp
region of the p21, Brip1, and PDK4 promoters, respectively. The sequences of the PCR
primers we used to amplify the p21 locus 16 were 5′-TGT ATG TGG CTC TGC TGG TG-3′
(forward) and 5′-CCT CCC CTC TGG GAA TCT AA-3′ (reverse). The sequences of the
PCR primers we used to amplify the Brip locus 17 were 5′-CTG TGT GAT TGG CTG ACT
GG-3′(forward) and 5′-TACAGCCACTCCTCCCTCTC-3′ (reverse). The sequences of the
PCR primers we used to amplify the PDK4 locus 18 were 5′-TCC TAG CGA CCT GGG
ATC TA -3′(forward) and 5′-CTA GAA AGG CCT GGC ACA GT-3′ (reverse). The
amplified DNA products were analyzed by real time qPCR using SYBR® Green and
confirmed by product melting curve analysis.
Results
MuRF1/MuRF2 DN mice exhibit a spontaneous cardiac hypertrophy from birth
We previously demonstrated that mice lacking either MuRF1 (MuRF1−/−) or MuRF2
(MuRF2−/−) do not exhibit a cardiac phenotype at baseline 7. To extend these previous
studies and to test for functional redundancy, we examined the cardiac phenotype of mice
lacking 3 or 4 of the MuRF1/MuRF2 alleles. Breeding MuRF1 +/− // MuRF2 +/− (to
generate MuRF1/MuRF2 DN mice) led to very few viable MuRF1/MuRF2 DN mice. We
therefore bred the limited number of surviving MuRF1/MuRF2 DN mice to either MuRF1+/
−//MuRF2−/− or MuRF1−/−//MuRF2+/− mice. This breeding strategy afforded us the
benefit of examining not only the phenotype of MuRF1/MuRF2 DN mice but also the
phenotype of mice lacking 3 of the 4 MuRF1 and MuRF2 alleles. These breedings resulted
in the birth of 76 mice lacking 3 of the 4 MuRF1/MuRF2 alleles (i.e. MuRF1−/−MuRF2+/−
or MuRF1+/−MuRF2−/−) and 25 MuRF1/MuRF2 DN mice. Of the 25 MuRF1/MuRF2 DN
mice that were born alive, 19 died between birth and post-natal day 23, while 6 survived to
adulthood. Using Mendelian principals to assume that the non-MuRF1/MuRF2 DN mice
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represented ~50% of the population, of the predicted 76 MuRF1/MuRF2 DN mice that
should have been born, 51 (67.1%) were unaccounted for by live births, as shown in Figure
1A. We propose that these mice died in utero due to cardiac defects as post-mortem
histological analysis consistently identified extensive cardiac hypertrophy and the presence
of fibrosis (illustrated in Supplemental Figure 1B, see blue extracellular matrix), with the
majority of the thoracic cavity taken up by the enlarged heart (Supplemental Figure 1A). In
contrast, MuRF1/MuRF2 DN mice that did not die did not exhibit any fibrosis anywhere in
their hearts (see Figure 1A, right column vs. adjacent middle column). Of the 25% MuRF1/
MuRF2 DN mice found dead after birth, the average age of death was 14.7+0.7 days (Figure
1B).
MuRF1/MuRF2 DN mice that survived into adulthood displayed normal activity and
breeding, despite a significant impairment in cardiac function determined by
echocardiography (see Figure 1C, Table 1), which did not progress with age (data not
shown). The earliest time point we investigated after birth (6 weeks of age) identified
significant defects in MuRF1/MuRF2 DN cardiac function (fractional
shortening=20.5+3.4% vs. other three groups FS=55.6+0.8%; ejection fraction=42.0+6.2 vs.
87.3+0.6%; N=3 & 5, respectively, p<0.01). At 12 weeks of age, MuRF1/MuRF2 DN mice
displayed significant cardiac dysfunction, as measured by a dramatic decrease in the
percentage of fractional shortening (FS) compared to wild type mice (21.9+2.2% vs.
56.6+0.7%, respectively). Mice in which 3 of the 4 MuRF1/MuRF2 alleles were missing
(MuRF1 −/− //MuRF2 +/− or MuRF1+/−//MuRF2−/−) showed no deficit in FS%
(55.4+1.1% and 58.1+0.8%, respectively) (Figure 1C). MuRF1/MuRF2 DN mice also
developed cardiac hypertrophy as indicated by increased heart weight/tibia length (Figure
1D), increased gross histological size (Figure 1E), and increased cardiomyocyte cross
sectional area (Figure 1F). Fibrosis and other gross defects were not detected in 12-week-old
MuRF1/MuRF2 DN mice histologically (Figure 2A), which was in sharp contrast to the
widespread fibrosis found in most MuRF1/MuRF2 DN mice that died within the first several
weeks of life (Supplemental Figure 1B). It is interesting to note that MuRF1 and MuRF2 are
found in cardiomyocytes, so the fibrotic response of the fibroblasts in these early deaths is
likely due to indirect and/or developmental effects of changes seen in the cardiomyocytes.
The cause of death in these mice that died in the first 2 weeks of life appeared to be heart
failure, as indicated by significant decrease in cardiac function and edematous lungs.
Interestingly, it is during this same window of time (i.e. post-natal days 5 through 14) that
mouse cardiomyocytes undergo a dramatic period of hypertrophic growth 19. This may
suggest that MuRF1 and MuRF2 may play a key regulatory role during this vital physiologic
developmental hypertrophy growth process as it is during this same time frame that most
MuRF1/MuRF2 DN post-natal deaths occur (average day 14.0±0.7). Transmission electron
microscopy indicated that hearts from the MuRF1/MuRF2 DN mice that died on average
day 14 exhibited disrupted sarcomeres, with both Z disc and M line defects, in addition to
gross abnormalities in mitochondria (Figure 2B). In contrast, no such defects and fewer
mitochondria were identified in skeletal muscle (gastrocnemius) of the same MuRF1/
MuRF2 DN mice by TEM (Supplemental Figure 1C). These findings suggest that overlap of
MuRF1 and MuRF2 function in sarcomeric stability may be less important in skeletal
muscle development compared to the developing heart.
MuR F1/MuRF2 DN hearts have discrete increases in hypertrophic “fetal gene” expression
Our results suggest that only 1 of the 4 MuRF1 and MuRF2 alleles is necessary to maintain
a phenotype comparable to wild type mice during cardiac and skeletal muscle development.
This led us to propose that MuRF1 and MuRF2 have redundant functions in developmental
cardiac growth, a finding that contrasts sharply with our observations that MuRF1, but not
MuRF2, regulates pathologic cardiac hypertrophy in adult mice in vivo 7. To determine
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whether the cardiac hypertrophy seen in the MuRF1/MuRF2 DN mice was associated with
“fetal gene” expression and pathologic hypertrophy, we assayed for the characteristic
upregulation of skeletal muscle actin, βMHC (myosin heavy chain), ANF (atrial natriuretic
factor), and BNP (brain natriuretic peptide) in MuRF1/MuRF2 DN, MuRF1−/−//MuRF2+/−
(Null Het), MuRF1+/−//MuRF2−/− (Het Null) and wild type mice. All four “fetal gene”
mRNA levels were significantly increased in the MuRF1/MuRF2 DN mice compared to
mice missing 3 of the 4 MuRF1/MuRF2 alleles or to wild type mice (Figure 2C). This
suggested that MuRF1/MuRF2 DN hearts underwent either pathologic cardiac hypertrophy
and/or exhibited an inhibition of cardiac development.
Global analysis of differential gene expression
Our physiologic, histologic, and Real Time PCR analysis of fetal genes demonstrated the
functional redundancy of MuRF1 and MuRF2: the absence of 3 of the 4 MuRF1/MuRF2
alleles resulted in normal cardiac phenotype, whereas the loss of all 4 alleles led to a
dramatic spontaneous cardiac hypertrophy. To investigate the redundancy of MuRF1 and
MuRF2 at the level of the transcriptome, we used microarray analysis to identify
differentially expressed genes in 12-week-old MuRF1/MuRF2 DN, MuRF1 −/− // MuRF2
+/− (Null Het), MuRF1 +/− // MuRF2 −/− (Het Null), and strain-matched wild type mice
(Figure 3; Supplemental Table 2). Based on the functional redundancy of MuRF1 and
MuRF2, we anticipated few differences between the wild type mice, and the 2 groups of
mice lacking 3 of the 4 alleles. However, an unsupervised cluster analysis of differentially
expressed genes between all 4 genotypes revealed a very different story. According to this
analysis, MuRF1 +/− // MuRF2 −/− mice share a similar cardiac gene expression profile
with WT mice (right 2 groups, Figure 3A), whereas the cardiac gene expression profile of
the MuRF1 −/− // MuRF2 +/− mice align more closely with the MuRF1/MuRF2 DN mice
(left 2 groups, Figure 3A). This latter finding was unexpected since both sets of mice lacking
three of the 4 MuRF1 and MuRF2 alleles were functionally identical to wild type mice.
To better delineate the relationships between the four groups of mice, we performed a
principle components analysis (PCA) of the four genotypes using the clustered gene set
(Figure 3B). A PCA is a linear transformation used to reduce the dimensions of a microarray
(containing thousands of genes) to a new coordinate system (x, y) by retaining
characteristics of the data that contribute most to the variance. This method for
characterizing or mathematically representing the relationship between individual
components of multiple complex data sets allows the determination of structure between
variables, in the present case between genotypes. The first principle component (PC1, which
accounts for 70% of the total variance across all of the samples) could not distinguish the
cardiac gene expression patterns in wild type and MuRF1 +/− // MuRF2 −/− mice (right
column, Figure 3B). This analysis also identified that the cardiac gene expression profile of
MuRF1 −/− // MuRF2 +/− and MuRF1/MuRF2 DN mice was substantially removed from
the other 2 groups, consistent with the unsupervised clustering. Interestingly, the second
principal component (PC2, 15% of the total variance) demonstrated similarities between the
cardiac gene expression profile of the MuRF1 −/− // MuRF2 +/− and the MuRF1 +/− //
MuRF2 −/− mice that were distinct from any similarities shared with either wild type or DN
mice. Consistent with this analysis, we identified only a few genes unique to MuRF1 −/− //
MuRF2 +/− (11) and MuRF1 +/−// MuRF2 −/− mice (33) (Supplemental Figure 4,
Supplemental Table 3).
We next compared the change in gene expression in the MuRF1/MuRF2 DN hearts
compared to all other groups. First, we identified all the genes differentially expressed from
wild type hearts, represented as the 3 circles in Figure 4A. We then compared these
differentially expressed genes between the MuRF1/MuRF2 DN, MuRF1 −/− // MuRF2 +/−
(Null Het), and MuRF1 +/− // MuRF2 −/− (Het Null) and identified 425 differentially
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expressed genes unique to the DN mice (Figure 4A). Analysis of the upstream promoter
regions of the 425 differentially expressed genes by TRANSFAC analysis using Gather
(http://gather.genome.duke.edu/) identified 8 transcription factor binding sites significantly
enriched in the promoter region of these genes (Figure 4B). Strikingly, 5 of the 8 binding
sites belonged to the E2F family of transcription factors, and were present in 40–85% of the
genes with TRANSFAC annotations (Figure 4B). The number of genes with predicted E2F
promoter binding sites was evenly distributed between up- and down-regulated genes (data
not shown), suggesting redundant regulation of E2F transcription activity may be mediated,
in part, by MuRF1 and MuRF2. TRANSFAC analysis also identified SREBf1, Cdc51, and
Egr(1–4) promoter binding sites in 46–78% of the genes differentially expressed in MuRF1/
MuRF2 DN mouse hearts (Figure 4B). With E2F1 so richly represented in this analysis in
the MuRF1/MuRF1 DN hearts, we performed Western blot analysis for E2F1 on all four
genotypes investigated in this study. At the protein level, E2F1 levels were not different
between the four MuRF1/MuRF2 genotype groups (Supplemental Figure 2A and 2B).
Genes differentially expressed in MuRF1/MuRF2 DN mice are involved in amino acid
metabolism and ligase activity
A higher order analysis of the differentially expressed genes using DAVID Bioinformatics
Resources 13 was next used to perform a functional annotation of genes differentially
expressed exclusively in the MuRF1/MuRF2 DN compared to all other groups (Figure 4C,
Supplemental Figure 3). The functional groups differentially expressed only in the MuRF1/
MuRF2 DN mice in relation to the other 3 groups included in this study were (Figure 4C,
Supplemental Figure 3): 1) muscle development and contraction (Figure 4D); 2)
angiogenesis and vascular development (Figure 4E); 3) extracellular matrix (Figure 4F); 4)
positive regulation of transcription (Figure 4G); and 5) the TCA cycle (Figure 4H). Detailed
functional enrichment analysis of these groups can be found in the supplemental results
section and Supplemental Figure 3. Upon extensive literature searches, we identified that,
although not previously reported in mice lacking MuRF1 and MuRF2 20, several of these
differentially expressed genes have been associated with both fetal cardiac development and
cardiac hypertrophy (see supplemental results section). The fact that we had identified genes
associated with cardiac hypertrophy was no surprise, given the extreme phenotype in the
MuRF1/MuRF2 DN. However, we were intrigued in the differences in gene expression
associated with the genotype of these mice (i.e. MuRF1−/−//MuRF2−/−) as opposed to the
phenotype (i.e. cardiac hypertrophy).
MuRF1−/−//MuRF2−/− hearts have decreased E2F1 occupancy at promoter regions of
multiple E2F1-regulated genes
Since no differences in E2F1 protein levels were identified between MuRF1−/−//MuRF2−/−
(DN), MuRF1−/−//MuRF2+/− (NH), MuRF1+/−//MuRF2−/− (HN), and wild type mice
(Supplementary Figure 2A and 2B), we hypothesized that E2F1 transcriptional activity was
regulated by MuRF1/MuRF2 expression in the heart. To test this hypothesis, we performed
chromatin immunoprecipitation (ChIP) using cardiac tissue from MuRF1−/−//MuRF2−/−
(DN) and their age-matched wild type controls to measure the occupancy of E2F1 in the
promoter regions of three genes, p21, Brip1, and PDK4, which we found to have
significantly different expression levels between MuRF1−/−//MuRF2−/− (DN) and wild
type hearts in microarray analyses. Primers to E2F1 binding sites in the promoter regions of
p21, Brip1, and PDK4, previously identified by Radhakrishnan et al. 16(15048076), Eelen et
al. 17 (18345034), and Hsieh et al. 18 (18667418), respectively, were designed to flank the
E2F1 binding sites for each of these genes in order to amplify DNA isolated by ChIP. A
significantly decreased amount of E2F1 occupancy in these promoters was identified in
MuRF1−/−//MuRF2−/− (DN) hearts compared to wild type for each of the E2F1 target
genes (Figure 5), including a role for MuRF1 and MuRF1. Given that the total E2F1 protein
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levels between these hearts does not differ, we propose that MuRF1 and MuRF2
redundantly prevent E2F1 from going in to the nucleus or they enhance E2F1 removal from
the nucleus by its ubiquitin ligase activities, to decrease its overall apparent interaction with
the promoter regions of E2F1 regulated genes.
Discussion
In this study, we identified for the first time that MuRF1 and MuRF2 play a necessary but
functionally redundant role in cardiac development in vivo. We found that MuRF1/MuRF2
DN mice are born with an extreme cardiac hypertrophy with a high rate of lethality peri-
natally within the first few weeks of life. However, in mice lacking 3 of the 4 MuRF1 and
MuRF2 alleles the cardiac phenotype was identical to that found in wild type mice. By
microarray analysis of cardiac gene expression, we identified that MuRF1−/−//MuRF2−/−
hearts had a number of differentially expressed many genes, which we identified having
E2F1 promoter regions using a bioinformatics analysis (TRANSFAC). Despite no
differences in E2F1 protein levels in MuRF1/MuRF2 DN mice (Supplemental Figure 5), we
did identify differences in E2F1 protein located on the promoter regions of E2F1-regulated
genes using ChIP assays (Figure 5). In this context, the present studies indicate that MuRF1
and MuRF2 may have overlapping function confined to the unique cardiac hypertrophy that
occurs during development, regulating key cellular processes controlled by the transcription
factor E2F1. Additionally, MuRF1 and MuRF2 had hypertrophy-independent effects, based
on principal components analysis, which were mediated by other transcriptions, as presented
in Supplemental Figure 4 and discussed in the online data supplement.
We identified that genes differentially expressed in MuRF1/MuRF2 DN compared to the
other three groups of mice had an overwhelming representation of E2F transcription factor
sites (Figure 4). Likewise, analysis of the differentially expressed genes in the MuRF1/
MuRF2 DN and MuRF1−/−//MuRF2+/− groups (Supplemental Figure 4) identified that
85% of the genes differentially expressed had E2F transcription factor sites in their promoter
region. However, the finding of 85% of the genes having E2F binding sites was not included
in our results since the p value was >0.05; regardless, it does point to a consistent trend in
our data sets. The identification of E2F1 transcription factor sites is intriguing because E2F1
in non-cardiac cells is known to be regulated by other ubiquitin ligases, including the
ubiquitin ligase MDM2 21, 22 and Cullin proteins. In association with ROC1 and SKP,
Cullins-1, 2, 3, and 5 also ubiquitinate E2F1 in non-cardiac cells 23. In cardiomyocytes,
E2F1 has the ability to drive quiescent cells into S phase in both neonatal and adult
cardiomyocytes 24, 25. E2F1 also regulates cardiomyocyte size 26, induces cardiomyocyte
cell proliferation without stimulating apoptosis 27, and activates autophagy and the intrinsic
death pathway 28. Given the prominent role of E2F transcription factors in cardiac cell cycle,
cell proliferation, cell death, and glucose oxidation, it is not surprising that they have a
prominent role in cardiac development. The role of E2F in the cardiac hypertrophy in the
present model, however, cannot be definitely interpreted as the cause of the hypertrophy.
Further studies will be necessary to determine if changes in E2F are directly causing the
phenotype, or are an indirect effect of the phenotype itself.
If MuRF1 and MuRF2 are redundantly regulating E2F1 to cause the present phenotype, the
mechanism is likely complex given the number of proteins involved in the E2F complex.
Mechanistically, the regulation of E2F1 transcription factors by MuRF1 and MuRF2 may
not be intuitive, given MuRF proteins role as a ubiquitin ligase that has been reported to
poly-ubiquitinate and degrade several proteins 2, 29. However, MuRF1, as well as other
ubiquitin ligases regulates proteins by several non-canonical ubiquitination pathways,
including mono-ubiquitination 30, 31. One way in which MuRF1 and MuRF2 may support
E2F1 to go to the nuclear may be by supporting its nuclear localization or inhibiting its
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nuclear export 30, 31, although this was not tested directly. Alternatively, we speculate that a
number of proteins are inhibitors of the E2F1 protein; one of the most well-studied group of
proteins which limit E2F1 transcriptional activity are pocket proteins, including
retinoblastoma susceptibility gene (Rb), p107, and p130—all of which are expressed in the
heart 32. Since the regulation of these pocket proteins in relation to their ability to inhibit
E2F1 has been found to be important for normal cardiac development and function 32,
MuRF1/MuRF2 could be exacting its activation of E2F1 transcriptional activity by targeting
pocket proteins for ubiquitin-dependent proteasomal degradation. Our data are consistent
with MuRF1 and MuRF2 redundantly promoting the recruitment of E2F1 to its binding sites
within the promoter regions of E2F1-regulated genes in the heart, since the absence of both
MuRF1 and MuRF2 leads to reduced E2F1 promoter occupancy by ChIP analysis. This may
be through mechanisms that directly support E2F1 stability, or through mechanisms that
promote the degradation of E2F1 inhibitors, resulting in more E2F1 at nuclear promoter
sites of E2F1-regulated genes.
Mice lacking E2F transcription factors have a cardiac phenotype and embryonic lethality
similar to that seen in our MuRF1/MuRF2 DN mice. For example, mice lacking E2F3 are
born at approximately 25% of the expected ratio, and the small proportion that survive to
adulthood exhibit growth retardation dependent on the dosage of E2F3 33. Crossing the
E2F3 null mice with mice having Retinoblastoma (Rb) mutations improves E2F3 null
mouse survival, suggesting a role of Rb in this process, since E2F-RB dimers occur in
vivo 33. Compound E2F3 +/− // E2F1 +/− heterozygous mice similarly develop congestive
heart failure, suggesting that the dosage of free activating E2F is critical to normal cardiac
development and function 33.
A recent study identified that mice lacking MuRF1 and MuRF2 created had a spontaneous
cardiac and quadriceps muscle hypertrophy, a decrease in body weight, and chronically
activated protein synthesis 20. They additionally identified that Carp, FHL2, and SQSTM1/
p62 were increased in MuRF1/MuRF2 DN hearts, but not in wild type, MuRF1 −/−, or
MuRF2 −/− mice, indicating that these may be redundant targets of MuRF1 and MuRF2 and
underlie the abnormal phenotype20. In the present study, we additionally demonstrate the
redundancy of MuRF1 and MuRF2 by showing that mice missing 3 of the 4 alleles (MuRF1
−/− // MuRF2 +/− and MuRF1 +/− // MuRF2 −/−) do not differ from strain-matched wild
type control mice. We additionally demonstrate the MuRF1 and MuRF2 redundantly
regulate E2F1 by microarray, TRASFAC analysis, and confirmation by ChIP assays of
E2F1 binding to p21, Brip1, and PDK4 promoter regions.
While this previous study identified a 74% post-natal mortality rate 20, the present study
estimated that approximately 67.1% of the MuRF1/MuRF2 DN mice died in utero, with an
additional 25% dying at day 14, and the remaining 6.7% surviving past the peri-natal period.
We also found that 4 of the 11 mice that we let survive into adulthood (i.e. not killed for our
studies) died at 3.3, 2.4, 2.1, and 0.7 months of age. In contrast, this previous study of
MuRF1/MuRF2 dKO mice all survived to 18 months, which is distinctly different than our
findings20. This may be due, in part, to the greater number of animals we evaluated overall.
Of these adult MuRF1/MuRF2 DN mice in the current study, one has survived 25 months
indicating the longevity of some MuRF1/MuRF2 DN mice if they survive the post-natal
death, which peaks at ~day 14. The present study emphasizes the developmental nature of
the defect in the hearts missing both MuRF1 and MuRF2, and suggests that the importance
of the redundant affects of these proteins predominantly is due to developmental cardiac
defects, a common cause of spontaneous abortion 34.
We identified comparable increases in the MuRF1/MuRF2 DN heart masses compared to
wild type hearts and hearts missing 3 of the 4 MuRF1/MuRF2 alleles. However, we did not
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identify a skeletal muscle hypertrophy in the gastrocnemius or tibialis anterior normalized
for tibia length. Interestingly, though, the soleus muscle was significantly decreased in the
MuRF1/MuRF2 DN mice compared to all the other genotypes tested. This is consistent with
the decreased body weight we identified in the MuRF1/MuRF2 DN at 12 weeks of age
(Supplemental Table 4) compared to all other groups. While Witt, et al. identified a similar
age-dependent decrease in body weight of the MuRF1/MuRF2 DN mice, they identified
hypertrophy in the quadriceps muscle at 18 months of age. There are many factors that may
account for these differences, including the differences in age, the background of the mice,
and the targeting strategies of the MuRF1 and MuRF2 alleles. However, the predominant
and profound changes in the cardiac phenotype are consistent between the two studies. The
mild changes in skeletal muscle suggest less of a redundant role of MuRF1 and MuRF2 in
vivo.
Despite their muscle specificity, mice lacking all four MuRF1 and MuRF2 alleles that died
at ~14 days of age, exhibited a diffuse fibrosis throughout their hearts, while those MuRF1/
MuRF2 DN mice that survive did not have any detectable fibrosis (Figure 1A). The
observed fibrosis may be related to the associated premature death that was not seen mice
that survived this 2 weeks period and had normal life spans (up to 25 months of age). Since
MuRF1 and MuRF2 are found in muscle, the effects of MuRF1 and MuRF2 deficiency on
fibroblast activation and secretion of fibrosis in the mice that died prematurely after birth is
due to indirect effects. The activation of fibrosis in cardiomyocyte-specific gene expression
has been described in multiple models 35–37 and speaks to the extensive cross talk between
cardiomyocytes and fibroblasts by inflammatory mediators 38 that control cardiac function.
A pivotal role of cardiomyocyte TGF-β, for example, has been implicated in the fibrosis
seen in pressure overload induced cardiac hypertrophy 39. Reparative fibrosis, in the context
of cardiomyocyte death, occurs to replace the dying cell and occurs in intermuscular spaces
focally 40. The more diffuse fibrosis that can occur, as described in the MuRF1/MuRF2 DN
mice that die at ~day 14, is regulated by cardiac fibroblasts that control the synthesis of
collagens and enzymes that degrade them (MMPs)40. It is unclear how the relatively small
subset of mice that survived the initial day 14 premature death associated with fibrosis
avoided the development of the diffuse fibrosis activated by indirect stimulation of
fibroblasts. And it is unexpected that this fibrotic response is absent in the surviving mice
with the severe cardiac dysfunction as fibrosis itself can contribute to cardiac dysfunction.
Since there is a strong relationship between myocardial extracellular matrix remodeling,
increased fibrosis, and decreased ventricular function 41, we hypothesize that the
pathophysiology of the acute death seen at ~day 14 is compounded by mechanisms seen in
the surviving mice (i.e. E2F1 mediated mechanisms) in addition to indirect fibrotic
mechanisms that contribute to the decreased function observed after birth, heart failure, and
sudden death not previously reported in this MuRF1/MuRF2 DN mouse model 20.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Non-standard Abbreviations and Acronyms
MuRF1 Muscle Ring Finger-1
MuRF2 Muscle Ring Finger-2
DN MuRF1/MuRF2 double null
S.M. actin skeletal muscle actin
ANF atrial natriuretic factor
βMHC β myosin heavy chain
BNP brain natriuretic peptide
CDKN1(p21) cyclin-dependent kinase inhibitor 1A
BRCA1 Breast cancer 2, early onset
Brip1 interacting protein C-terminal helicase 1
PDK4 pyruvate dehydrogenase kinase, isozyme 4
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Figure 1. MuRF1 −/− // MuRF2 −/− (DN) mice die in utero and peri-natally and exhibit a
spontaneous cardiac hypertrophy
A. Analysis of the fate of MuRF1/MuRF2 DN pups born from breedings of MuRF1/MuRF2
DN mice and either MuRF1−/−MuRF2+/−or MuRF1+/−MuRF2−/− mice (N=76 estimated
from the 76 non-MuRF1/MuRF2 DN mice). B. Graphical representation of the average day
of death of mice with varying genotypes (N=22). C. Echocardiograms from 12-week-old
mice of varying genotype. MuRF1/MuRF2 DN mice exhibit a pronounced decrease in
cardiac function. D. Cardiac hypertrophy was determined by measuring the ratio of
increased heart weight/tibia length. E. Paraffin cross sections through the hearts of mice
with varying genotypes. F. Measurement of myocyte cross sectional area. A One-Way
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ANOVA was performed to determine significance, followed by a multiple comparison
procedures (Holm-Sidak method) to determine significance between groups. *p<0.001
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Figure 2. MuRF1/MuRF2 DN hearts exhibit significant increases in fetal gene expression and
disrupted sarcomere organization and mitochondria
A. Histological analysis of 12-week-old hearts. B. Electron microscopic analysis of wild
type and MuRF1/MuRF2 DN hearts. C. Markers of cardiac hypertrophy are increased in 12-
week-old MuRF1/MuRF2 DN hearts. Data in all panels represent at least five mice/group. A
One-Way ANOVA was performed to determine significance, followed by a multiple
comparison procedures (Holm-Sidak method) to determine significance between groups.
*p<0.001
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Cluster analysis of differentially expressed genes in 12-week-old MuRF1/MuRF2 DN,
MuRF1 −/− // MuRF2 +/− (NH), MuRF1 +/− // MuRF2 −/− (HN), and strain-matched wild
type (WT) hearts. Represented are differentially expressed genes with a fold change > 2.0, p
value cut-off < 0.05, analyzed by One-Way ANOVA and post-hoc by Tukey HSD and
Benjamini-Hochberg multiple testing correction. A. An unsupervised clustering analysis was
then performed on genes differentially expressed statistically. B. A principal components
analysis was then performed on the 14 individual data sets included in the analysis, which
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determined similarities between wild type and MuRF1 +/− // MuRF2 −/− (HN) hearts by
principal component 1, accounting for 70% of the differences between the data sets.
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Analysis of genes differentially expressed only in MuRF1/MuRF2 DN hearts. Represented
are differentially expressed genes with a fold change > 2.0, p value cut-off < 0.05, analyzed
by One-Way ANOVA and post-hoc by Tukey HSD and Benjamini-Hochberg multiple
testing correction. A. A Venn diagram representation of the genes analyzed for common
transcription factor binding sites by TRANSFAC analysis and enriched functional groups by
DAVID analysis. Genes differentially expressed in the MuRF1/MuRF2 DN, MuRF1 +/− //
MuRF2 −/− (HN), and MuRF1 −/− //MuRF2 +/− (NH) compared to wild type mice were
compared. The 425 genes unique to the MuRF1/MuRF2 DN mice were investigated further.
B. TRANSFAC analysis using Gather of the putative binding sites in the promoter region of
the 425 genes differentially expressed in MuRF1/MuRF2 DN as a percentage the annotated
genes. C. A cluster analysis of the higher ordered DAVID analysis of the annotated genes
revealed enriched functional groups in: D. Muscle Development and Contraction; E.
Angiogenesis and vascular development; F. Extracellular matrix; G. TCA cycle; and H.
Positive regulation of transcription. The functional enrichment of the functional categories
by the heat map in orange (see insert for key).
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Figure 5. E2F1 occupancy in the promoter regions of E2F1 regulated genes, p21, Brip1, and
PDK4, is significantly decreased in MuRF1−/−//MuRF2−/− (DN) hearts compared to wild type
Fresh cardiac tissue was cut into 1mm pieces and crosslinked with formaldehyde in order to
establish protein-DNA complexes. Crosslinked tissue was lyzed, chromatin was extracted,
and sonication was performed as described in the Materials and Methods. The resulting
chromatin was immunoprecipitated using antibodies specific to E2F1, histone H3 (positive
control), or IgG (negative control). Following immunoprecipitation, protein-DNA
complexes were decrosslinked and DNA was extracted. Immunoprecipitated DNA was
submitted to RT-PCR analysis using primers flanking the E2F1 binding sites within the
promoter regions of p21, Brip1, and PDK4. CT-values were compared to input CT values to
generate %input values for each experimental group and final data was normalized to
negative control (IgG). Resulting data show that the amount of immunoprecipitated DNA
corresponding to the E2F1 binding regions of p21, Brip1, and PDK4 gene promoters was
significantly decreased in MuRF1−/−//MuRF2−/− hearts (gray bars) compared to wild types
(black bars). At Student’s t-test was used to determine the significance between genotypes.
*p<0.01
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Table 1
Echocardiography of Dimensions and Function in MuRF1/MuRF2 DN, wild type, MuRF1−/−MuRF2+/−
(NH), and MuRF2+/−MuRF2−/− (HN) mice at 12 weeks of age. Data represents an approximate even
distribution of male and female mice. *p<0.001 vs. MuRF1/MuRF2 wild type, MuRF1+/−MuRF2−/−, and







MuRF1 +/− MuRF2 −/−
(HN) (N=5)
BW (g) 26.5±0.9 23.3±3.5 27.1±1.15 23.0±2.6
HW/TL (mg/mm) 9.1±0.9 17.4±1.6* 10.9±0.4 9.2±0.2
LV mass index (mg) 110.3±7.3 206.2±20.2* 104.3±5.4 103.0±13.0
LVMass/BW (mg/g) 4.2±0.3 8.88±0.47* 4.2±0.2 4.5±0.6
HR (bpm) 609.0±29.3 644.6±24.3 643.6±14.3 612.2±22.6
IVSTD (mm) 0.99±0.02 1.14±0.03* 1.04±0.02 1.01±0.01
IVSTS (mm) 1.57±0.13 1.47±0.01 1.69±0.07 1.70±0.05
PWTD (mm) 0.98±0.02 1.08±0.03* 1.01±0.01 0.97±0.01
PWTS (mm) 1.67±0.04 1.20±0.03* 1.68±0.08 1.52±0.03
LVEDD (mm) 2.94±0.13 3.98±0.24* 2.90±0.20 2.84±0.20
LVESD (mm) 1.24±0.06 3.23±0.30* 1.21±0.06 1.20±0.06
EF (%) 88.0±0.6 44.3±3.9* 89.2±0.4 83.4±4.3
Transthoracic echocardiography on unanesthetized mice. BW, body weight; HW, heart weight; TL, tibia length; HR, heart rate; LV mass index
[(ExLVD3d-LVED3d) × 1.055]; ExLVD, external left ventricular diameter; bpm, heart beats per minute; IVSTD, interventricular septal thickness
in diastole; IVSTS, interventricular septal thickness in systole; PWTD, posterior wall thickness in diastole; PWTS, posterior wall thickness in
systole; LVEDD, left ventricular enddiastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, calculated as
(LVEDD-LVESD)/LVEDD × 100; ND, not determined.
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